Expert Insights on Emerging Data from the 2014 Global Congress on

MS

Program Goals

Disclaimers

Current Clinical Data on New and Emerging

MS Disease-Modifying Therapies

Glatiramer Acetate

Dimethyl Fumarate

Pegylated Interferon

Daclizumab HYP

Daclizumab HYPMRI Results

You must view all 3 sections of this activity to earn CME credit.

Please click on the next section title to continue.

Biomarkers, Safety, and New Treatment Targets

MS Therapy Is Cost-effective

Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut

Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut (cont)

NatalizumabStopping Treatment

Natalizumab (cont) PML

Natalizumab (cont)Extended Dosing

PML Risk With Other DMTs

MS Management Algorithms

NEDA

You must view all 3 sections of this activity to earn CME credit.

Please click on the next section title to continue.

On the Horizon

RemyelinationAnti-LINGO

RemyelinationHistamine 3 Receptor Agonist

Neuroprotection

Other Therapies on the Horizon

Other Therapies on the Horizon (cont)

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)